SLU-PP-332

The SLU-PP-332 evidence base cited here is 3 sources — 3 preclinical. Critically, that evidence is almost entirely preclinical (animal and in-vitro) — no human clinical trials are cited, so efficacy and safety in people remain unproven. Regulatory status: Not FDA-approved (never tested in humans).

• SLU-PP-332 is NOT a peptide — it's a synthetic small molecule (~290 Da), a pan-ERR (estrogen-related receptor) agonist with preference for ERRα, developed at Saint Louis University as an 'exercise mimetic'.
• It activates exercise-like metabolic programs (PGC-1α, AMPK, mitochondrial biogenesis, fat oxidation) without physical activity — in ANIMALS. There are NO human clinical trials and NO established human dose.
• All efficacy data (e.g. ~12% weight loss in 28 days, big endurance gains) is from rodents at 50 mg/kg IP. The compound is repeatedly flagged 'not for human use'; products sold for human consumption are illegal/dangerous.

SLU-PP-332 is an experimental 'exercise mimetic' — a small molecule that switches on the metabolic gene programs normally triggered by aerobic exercise. In obese and aging mice it drives weight loss, raises energy expenditure, and improves endurance without the animals exercising more or eating less.

The crucial framing: this is entirely preclinical. There are no human trials, no human dose, and it is explicitly sold for research only. An oral formulation is reportedly in development, but as of now SLU-PP-332 is a lab compound, not a usable supplement. Everything below is research context, not medical guidance.

SLU-PP-332 is a synthetic small molecule (~290 Da, formula C₁₈H₁₄N₂O₂) — chemically a benzohydrazide, not a peptide. It is a pan-agonist of the estrogen-related receptors (ERRα/β/γ) with ~2.3-fold selectivity for ERRα (EC50 ~98 nM) over ERRβ and ERRγ.

The ERRs are orphan nuclear receptors that act as master regulators of cellular energy metabolism — which is why activating them mimics the metabolic adaptations of exercise.

By activating ERRα/β/γ, SLU-PP-332 upregulates the energy-metabolism gene network: it raises PGC-1α (the master regulator of mitochondrial biogenesis), activates AMPK, increases mitochondrial density (reported up to ~1.8-fold), enhances oxidative phosphorylation and ATP output, promotes fatty-acid oxidation, and shifts muscle toward oxidative (type IIa) fibers. The net effect in animals reproduces the acute genetic program of aerobic exercise — hence 'exercise mimetic'. None of this has been demonstrated in humans.

There is NO established human dose. Every protocol in the literature is an animal study, and the compound is not validated for human use in any form.

• Animal studies used ~50 mg/kg intraperitoneal (IP), twice daily — a research route, not a human one
• No human pharmacokinetics, no human dose, no human safety data
• An oral formulation is reportedly in development; until then there is no usable human protocol

Treat any 'human dosing protocol' for SLU-PP-332 as fabricated — none exists. It has never been administered in a human trial.

SLU-PP-332 is water-insoluble, so it cannot be reconstituted with bacteriostatic water like the peptides on this site — it requires a DMSO-based solvent system. This is a lab-reagent handling protocol, not an injection prep.

• Prepare a stock in anhydrous DMSO (~50–125 mg/mL), then dilute for in-vivo work (e.g. 10% DMSO + 10% Tween 80 + 80% PBS, final DMSO ≤10%).
• Store stock at −80°C (long-term) or −20°C (shorter); avoid freeze-thaw cycles.
• Source from reputable chemical suppliers (e.g. Cayman, Sigma-Aldrich) with a COA (>98%) — no GMP/USP grade exists for human use.

In rodents and dogs the profile was favorable (no liver/kidney/cardiac toxicity reported, no hormone suppression, not a stimulant), with minor cholesterol/liver-enzyme changes in some studies. But the human safety profile is COMPLETELY UNKNOWN — it has never been tested in people. Legal status varies, products marketed for human consumption are illegal/dangerous, and no one should use an untested experimental compound outside a sanctioned, supervised study.

• Metabolic syndrome (2024, J Pharmacol Exp Ther): diet-induced obese mice, 50 mg/kg IP twice daily, 28 days — ~12% weight loss, ~25% higher fatty-acid oxidation, improved glucose tolerance, no appetite suppression.
• Aging kidney (2023, Am J Pathol): 21-month-old mice, 8 weeks — reduced albuminuria and restored mitochondrial architecture.
• Acute aerobic-exercise response (2023, ACS Chem Biol): mice, 50 mg/kg IP — increased running time/distance and more type IIa muscle fibers.

Every result is in animals. Read the impressive numbers (weight loss, endurance) as rodent findings — human efficacy and tolerance are unknown.

SLU-PP-332 is a research chemical, not FDA-approved, and has never been tested in humans. It is sold for laboratory research only; products marketed for human consumption are not legitimate.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.